CONCLUSION AND KEY MESSAGE

Slides:



Advertisements
Similar presentations
Chapter 9: The relationship between physical activity and anxiety and depression Can physical activity beat the blues and help with your nerves?
Advertisements

Depression—There are at least two sides to every story.
BACKGROUND & OBJECTIVES Approximately 1 in 20 U.S. adults age 50 and over have depression 1 More than half of these older adults have depression with severe.
Arthur E. Kelley, MD Medical Director, Partnership for Community Care (CCNC) Psychiatric Consultant, Cornerstone Healthcare, High Point, NC.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September-October 2007.
PICO Deep brain stimulation for treatment resistant depression. Clinical reality ?
Journal Club Alcohol and Health: Current Evidence September-October 2005.
Are Benzodiazepines Still the Medication of Choice for Patients With Panic Disorder With or Without Agoraphobia? By : s.bruce, PhD et al (Am J Psychiatry.
Depression Measures Health Disparities Collaborative 2005.
Bellwork In your IAN, at the top of what will be today’s notes, define normal In your own words When you are done to your partner and share with each other.
Nasa Valentine, MD Wael Hamade, MD Than Luu, MD
Treatment for Adolescents With Depression Study (TADS)
Depression: An overview Most cases are managed in primary care Role of secondary care largely applies to severe and complex cases Secondary care would.
Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.
Transcranial Magnetic Stimulation (TMS)
STAR*D Objectives Compare relative efficacy of different treatment options –Goal is REMISSION, not just “response” –Less than half of patients with depression.
Smoking and Mental Health Problems in Treatment-Seeking University Students Eric Heiligenstein, M.D. University of Wisconsin-Madison Health Services Stevens.
Depression Management Presentation 1 of 3 Documented diagnosis PHQ tool Depression care assessment.
Clinical Presentation Worry about: –health –job and finances –competence –acceptance –family, friends, relationships –minor matters Unexplained physical.
An Innovative Mental Health Center. Reasons for HOPE: Advances in Mental Health Care Presented by Paul E. Keck, Jr., M.D. President and Chief Executive.
EBM --- Journal Reading Presenter :黃美琴 Date : 2005/10/27.
©2016 MFMER | slide-1 Patient screening tools associated with prediction of depression remission at six months Kurt B. Angstman, MS MD Professor of Family.
Prevalence of psychiatric morbidity in the primary health clinic attendees in Kuwait Dr. Sulaiman Alkhadhari, Dr. Aseel Omran Alsabbrri, Dr.Ibrahim H.A.Mohammad,
Journal Club Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Rebecca Luke 2/9/2016.
©2015 MFMER | slide-1 PTSD: Worsening outcomes for comorbid depression… even with collaborative care management. Kurt B. Angstman, MS, MD Professor of.
Comorbidity and Multimorbidity: Measurement and Interventions Holly M. Holmes, MD, MS Dept of General Internal Medicine.
Depression in chronic kidney disease 신장내과 R4 정우진 Mini topic.
Depression, Worry, and Psychosocial Functioning
Association of Body Mass Index (BMI) and Depression Severity
Some epidemiological principles and methods
Landon Marshall, Pharm. D. , Matt Hill, Pharm. D. , Jim Wilson, Pharm
Sofija Zagarins1, PhD, Garry Welch1, PhD, Jane Garb2, MS
Concordance Of Clinical & Electronic Data In Assessment of Depression: Findings From The Smartphone And Online Usage Based Evaluation For Depression (SOLVD)
Analysis of a New Method for Studying Placebo Effects
Mobile Cognitive Training for Young Adults with Depressive Symptoms
Is High Placebo Response Really a Problem in Clinical Trials?
Development and Implementation of a Tobacco Cessation Toolkit
Obsessive Compulsive Disorder (OCD) Abdulaziz S. Alsultan
Transcranial direct current stimulation (tDCS) in therapy-resistant depression: Preliminary results from a double-blind, placebo-controlled study. U. Palm,
Quality of Medical Care Received by Individuals with Mental Illnesses
PECULLIARITIES OF CHRONIC PAIN ASSESSMENT AND MANAGEMENT
Psychological Disorders and Therapies
Pharmacological and Behavioral
WG Mental Health Work Group Examination of Anxiety and Depression in Cameroon, Canada, India and the United States Islay Mactaggart Research Fellow in.
Ferhat Yaylacı, Handan Özek Erkuran, Murat Eyüboğlu***
Predictors of good and poor response in GAD
Prevalence and Impact of Anxiety Disorders in
Replace with logo Results Objectives Results Introduction Conclusion
PHQ2 Screening Negative PHQ2 Screening Positive
The mehealth Portal and CQN ADHD Measurement
Bruce Waslick, MD Medical Director UMass / Baystate MCPAP Team
A2 unit 4 Clinical Psychology
Laura Donato [Mentor: Wendy Bjerke] College of Health Professions
Matthew H. Liang, MD Malcolm P. Rogers, MD Ira R. Katz, MD, PhD
Dr. Muhammad Ajmal Zahid Chairman, Department of Psychiatry,
Rhematoid Rthritis Respiratory disorders
Diabetes and Psychiatric Disorders: Can they Co-exist?
Effective and humane care for all with mental, neurological,
Clinical Presentation
Brief Introduction of CCMD-3: Present and Future (Toward Integration In International Classification) Beijing Huilongguang Hospital.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Generalized Anxiety Disorder: Clinical Features and Diagnosis
Predictors of good and poor response in GAD
Medical Approach Physicians began using medical models to review the physical causes of these disorders. Etiology: Cause and development of the disorder.
Interreg-IPA Cross-border Cooperation Programme Romania-Serbia
Classification and Treatment Plans
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Facts and stats about mood disorders
Presentation transcript:

CONCLUSION AND KEY MESSAGE Deep TMS for Comorbid Major Depressive Disorder and Anxiety – A Brief Report of Patients in a Real-World Practice Sarit Hovav, M.D.1, Kevin Kinback, M.D.2 1Creighton University / University of Nebraska Medical Center; 2Loma Linda University School of Medicine / Advanced TMS Center INTRODUCTION METHODS DISCUSSION TMS with higher pulse sequence produced higher than expected results for response but lower than expected remission rates using the self-rated PHQ-9 scale. Using the gold-standard HAM-D scale, there was a 30% remission rate and 10% response rate. The remaining 60% of patients all had clinical improvement.13 This is comparable to the large multicenter study done by Brainsway where response and remission rates were 38.4% and 32.6%, respectively; however these were at 5 weeks,14 rather than the standard 4 week treatment that is currently recommended and is done in this study. As it has been stated in the introduction, several previous studies show that concurrent anxiety predicts poorer responses in patients with depression, and this may be affecting the remission PHQ-9 scores, which rely on the patients’ insight. Limitations to the study include: The PHQ-9 is a self-report measure and may not compare with clinician-rated scores. A relatively small sample size. No specific anxiety scale was used. Severe depression is a public health priority due to its associated disability. It is estimated that 16.6% of the population will experience depression in their lifetime.1 Severe depression is the leading cause of years lost due to disability (YLD) worldwide in low, middle, and high income countries, representing a total of 25% of total YLD from all causes.2 Deep Transcranial Magnetic Stimulation (dTMS) received FDA clearance in 2013 for the treatment of major depressive disorder (MDD). As of yet, there are no published post-marketing outcome data in "real world" practices. The American Psychiatric Association recommends TMS after failure of one prior antidepressant.3 There are concerns over equity in access to TMS for certain populations, since third party reimbursements are sparse in most states, in comparison to ECT. This makes TMS a sort of “boutique treatment” whereby it can only be accessed by higher income individuals. Anxiety symptoms often occur in patients with depression, and it has been found to carry a poor clinical prognosis; predicting a more chronic course, a more severe depressive episode, lower rates of treatment response, and a higher suicide risk.4-8 Further, patients with anxiety tend to use more complementary and alternative treatments9 without disclosure to their providers and therefore may have interference with first line pharmacotherapy treatments. Study Design: Deep TMS was administered using the H-coil system whereby the left prefrontal cortex is preferentially stimulated.10 Parameters of treatment were 18Hz, 2 second train duration, 36 pulses per train, and a 20 second inter-train interval. All patients were titrated up to a stimulation intensity of 120% of motor threshold, and given a daily average of 73 trains, above the manufacturer recommended 55. Patients were also given an additional right sided protocol for management of anxiety using 1Hz at 1 pulse per second. On average, 183 pulses were administered per session, with level of anxiety severity as gauged by a physician guiding the amount. There is no recommended use of this H-Coil for right-sided treatment. The decision to continue or discontinue medication was made on a case-by-case clinical basis. Clinical Assessment: Patients were monitored using both the HAM-D and the self-rated PHQ-9 scale. Question number 10 on the HAM-D was used to assess anxiety symptoms. For the HAM-D, response was defined as a minimum reduction of 47% and remission of a final score of ≤7.11 For the PHQ-9, response was defined as a reduction of ≥5 points from baseline, partial response is defined as <10, and remission was defined as either a final score of <5 or zeroes on both questions 1 and 2.12 To determine response in anxiety symptoms, question 10 was reviewed. Maximum anxiety score is a 4, and minimum is a zero. Data Analysis: Data were analyzed with IBM SPSS Statistics for Windows, version 21.0 (SPSS, Armonk, NY: IBM Corp). Group changes were assessed with a paired t-test comparing baseline and final values. Statistical significance was set at p<0.05 two-tailed. CONCLUSION AND KEY MESSAGE This is the first published report of dTMS administered using greater amounts of pulses along with right-sided treatment. Our results show significant statistical and clinical improvement in depression and anxiety using this novel pulse sequence, but it remains unclear if these results would hold true in larger more standardized clinical trials. Augmented TMS protocols such as these used earlier in the illness course may prevent complex psychopharmacology, ECT, or inpatient hospitalization. Formal, prospective studies are needed to determine standardized dTMS protocols. RESULTS OBJECTIVES To examine 10 patients who received dTMS for comorbid depression and anxiety without the constraints of a clinical trial whereby dTMS is administered as a monotherapy for major depression and comorbidities are typically exclusionary. To determine if extending the amount of TMS trains and adding low frequency right sided pulses can improve depression response and remission rates after 4 weeks of dTMS treatment. REFERENCES Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of general psychiatry. Jun 2005;62(6):593-602. Üstün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJL. Global burden of depressive disorders in the year 2000. The British Journal of Psychiatry. May 1, 2004 2004;184(5):386-392. American Psychiatric Association (2010) (eds: Gelenberg, AJ, Freeman, MP, Markowitz, JC, Rosenbaum, JF, Thase, ME, Trivedi, MH, Van Rhoads, RS). Practice Guidelines for the Treatment of Patients with Major Depressive Disorder, 3rd Edition Sherbourne CD, Wells KB. Course of depression in patients with comorbid anxiety disorders. Journal of affective disorders. 1997;43(3):245-250. Grunhaus L, Harel Y, Krugler T, Pande AC, Haskett RF. Major depressive disorder and panic disorder. Effects of comorbidity on treatment outcome with antidepressant medications. Clin Neuropharmacol. 1988;11(5):454-461. Coryell W, Endicott J, Winokur G. Anxiety syndromes as epiphenomena of primary major depression: outcome and familial psychopathology. The American journal of psychiatry. 1992;149(1):100-107. Brown C, Schulberg HC, Shear MK. Phenomenology and severity of major depression and comorbid lifetime anxiety disorders in primary medical care practice. Anxiety. 1996;2(5):210-218. Allgulander C, Lavori PW. Causes of death among 936 elderly patients with 'pure' anxiety neurosis in Stockholm County, Sweden, and in patients with depressive neurosis or both diagnoses. Compr Psychiatry. 1993;34(5):299-302. Bystritsky A, Hovav S, Sherbourne C, et al. Use of Complementary and Alternative Medicine in a Large Sample of Anxiety Patients. Psychosomatics. May-Jun 2012;53(3):266-272. Roth Y, Padberg F, Zangen A. Transcranial magnetic stimulation of deep brain regions: principles and methods. In: Marcolin MA, Padberg F, eds. Transcranial Brain Stimulation for Treatment of Psychiatric Disorders. Vol 23: Karger; 2007:204-224. Riedel M, Moller HJ, Obermeier M, et al. Response and remission criteria in major depression--a validation of current practice. J Psychiatr Res. 2010;44(15):1063-1068 Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatric Annals. 2002;32(9):509-515 Leonard BE. Antidepressants. Basel; Boston: Birkhäuser Verlag; 2001. Roth Y, Zangen A. Deep TMS: Method and Clinical Results. Magnet. 2014;2(1). METHODS Study Subjects: We examined a retrospective cohort of ten patients, ages 20-74, who received dTMS for treatment-resistant MDD with an additional protocol aimed at treating their comorbid anxiety. All patients were diagnosed with MDD by a psychiatrist (KK) and met criteria for at least depression using the gold-standard Hamilton Depression Rating Scale (HAM-D). Mild Depression: 30% Moderate Depression: 40% Severe Depression: 30% All patients have failed at least 2 antidepressants in the current episode of depression. According to the PHQ-9, at the end of treatment 50% of patients met criteria for response, 20% met criteria for a partial response, and none met criteria for remission. Baseline PHQ-9 (mean=16.70, SD=5.52) to the end of treatment at 4 weeks (mean=11.6, SD=4.33) shows significant differences between groups; t(9)=3.36, p=0.008. According to the HAM-D, at the end of treatment 10% met the criteria for response and 30% met criteria for remission. The remaining 60% had a decrease in HAM-D score between 27-43% with a mean of 36.2% reduction of score. Baseline HAM-D (mean=21.0, SD=4.00) to the end of treatment at 4 weeks (mean=11.6, SD=3.81) also show significant differences between groups; t(9)=6.87, p<0.001. Patients also showed significant improvement in anxiety with baseline question 10 on HAM-D (mean=2.3, SD=1.06) to end of treatment at 4 weeks (mean=1.2, SD=0.63); t(9)=3.97, p=0.003.